Assessment of the Effectiveness of Budesonide MMX for Active, Mild-to-moderate Ulcerative Colitis in the Polish Sub-group of the CORE Practice Prospective Multi-centre Observational Study

Overview

Journal Prz Gastroenterol

Publisher Termedia

Specialty Gastroenterology

Date 2023 Aug 4

PMID 37538282

Authors

Maciej Jesionowski

Grazyna Rydzewska

Silvio Danese

Kristine Paridaens

Affiliations

Soon will be listed here.

Abstract

Introduction: Budesonide MMX is approved for induction of remission in mild-to-moderate active ulcerative colitis (UC) in adults in whom 5-ASA is not sufficient. There is a lack of data on its effectiveness and safety in clinical practice.

Material And Methods: The CORE Practice study was a multi-centre prospective, observational study of mild-to-moderate UC-patients treated with Budesonide MMX 9 mg for up to 8 weeks (induction). Enrolled patients had previously been prescribed Budesonide MMX 9 mg in accordance with the SmPC within a 5-day time window. The primary endpoint was the percentage of patients achieving a decrease ≥ 3 points in the UCDAI clinical sub-score at the end of the induction treatment. Other endpoints were clinical remission (decrease ≤ 1 in UCDAI clinical sub-score), resolution of symptoms, change in Short Inflammatory Bowel Disease Questionnaire (SIBD-Q) score, treatment satisfaction, and tolerability. This report presents results from the Polish study sites.

Results: The data from a Polish subgroup of 181 patients with mild-to-moderate UC were analysed. Clinical improvement ≥ 3 points in the UCDAI at the end of treatment induction was achieved in 63.8% patients. Clinical remission was observed in 55.9% of patients at the end of the induction treatment. Full resolution of symptoms (rectal bleeding = 0 and stool frequency = 0) at the end of the Budesonide MMX treatment was achieved in 52.5% of patients. Significant improvement in quality of life was seen in mean SIBD-Q total score from 40 points at baseline to 56 points at last assessment ( < 0.001). A treatment satisfaction score of more than 8 out of 10 was observed in 72.9% of patients. One patient discontinued Budesonide MMX due to an adverse event that was related to the study drug, which counted for less than 1% of patients.

Conclusions: The data from the Polish subgroup of the real-life study CORE Practice confirms the clinical efficacy of Budesonide MMX 9 mg in the majority of patients with active mild-to-moderate UC. Budesonide MMX was safe and well tolerated. The therapy was satisfactory for patients and showed a beneficial effect on the patients' quality of life.

References

Rubin D, Cohen R, Sandborn W, Lichtenstein G, Axler J, Riddell R . Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017; 11(7):785-791. PMC: 5881669. DOI: 10.1093/ecco-jcc/jjx032. View

Lodyga M, Eder P, Bartnik W, Gonciarz M, Klopocka M, Linke K . New pharmaceuticals in inflammatory bowel disease. Prz Gastroenterol. 2015; 10(2):57-60. PMC: 4631272. DOI: 10.5114/pg.2015.52702. View

Irvine E, Zhou Q, Thompson A . The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996; 91(8):1571-8. View

Brokelman R, Haverkamp D, van Loon C, Hol A, Van Kampen A, Veth R . The validation of the visual analogue scale for patient satisfaction after total hip arthroplasty. Eur Orthop Traumatol. 2012; 3(2):101-105. PMC: 3389603. DOI: 10.1007/s12570-012-0100-3. View

Gross V . Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis. Expert Opin Pharmacother. 2008; 9(7):1257-65. DOI: 10.1517/14656566.9.7.1257. View

Sandborn W, Danese S, DHaens G, Moro L, Jones R, Bagin R . Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015; 41(5):409-18. PMC: 6681012. DOI: 10.1111/apt.13076. View

Salice M, Rizzello F, Calabrese C, Privitera Hrustemovic H, Gionchetti P . Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2019; 13(7):607-613. DOI: 10.1080/17474124.2019.1621745. View

Burisch J . Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan Med J. 2014; 61(1):B4778. View

Tenjarla S, Romasanta V, Zeijdner E, Villa R, Moro L . Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv Ther. 2007; 24(4):826-40. DOI: 10.1007/BF02849976. View

10.

Lewis J, Chuai S, Nessel L, Lichtenstein G, Aberra F, Ellenberg J . Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008; 14(12):1660-6. PMC: 2597552. DOI: 10.1002/ibd.20520. View

11.

Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M . Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. United European Gastroenterol J. 2019; 7(9):1164-1170. PMC: 6826517. DOI: 10.1177/2050640619864257. View

12.

Sandborn W, Travis S, Moro L, Jones R, Gautille T, Bagin R . Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012; 143(5):1218-1226.e2. DOI: 10.1053/j.gastro.2012.08.003. View

13.

Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U . Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017; 11(7):769-784. DOI: 10.1093/ecco-jcc/jjx009. View

14.

Sutherland L, Martin F, Greer S, Robinson M, Greenberger N, Saibil F . 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987; 92(6):1894-8. DOI: 10.1016/0016-5085(87)90621-4. View

15.

Eder P, Lodyga M, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M . Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol. 2023; 18(1):1-42. PMC: 10050986. DOI: 10.5114/pg.2023.125882. View

16.

Danese S, Hart A, Dignass A, Louis E, DHaens G, Dotan I . Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterol. 2016; 3(1):e000092. PMC: 4873945. DOI: 10.1136/bmjgast-2016-000092. View

17.

Travis S, Danese S, Kupcinskas L, Alexeeva O, DHaens G, Gibson P . Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2013; 63(3):433-41. PMC: 3933176. DOI: 10.1136/gutjnl-2012-304258. View

18.

Bonovas S, Nikolopoulos G, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S . Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. Br J Clin Pharmacol. 2017; 84(2):239-251. PMC: 5777428. DOI: 10.1111/bcp.13456. View